International Study Confirms Significant, Sustained IOP and Medication Reduction Following Standalone Implantation of Glaukos’ iStent inject® in Glaucoma Patients with Substantial Disease Burden

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, announced today that results of an independent, international study published in Advances in Therapy showed standalone implantation of the iStent inject® Trabecular Micro-Bypass System in eyes with subst

Full Story →